Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 28 for “"STING agonists"”.
-
A High Throughput Assay for the Detection of Stimulator of Interferon Genes (STING) Agonists
… immune response against tumors. In this regard, STING, a receptor of cyclic dinucleotides (CDN), has come to the forefront of immuno-oncology. Activation of STING has been shown to induce profound CD8 T cell-led immune reaction against immunologically suppressed tumors, as well as a memory …
-
STING IN TUMOR CELLS IS REQUIRED FOR THE ANTI-CANCER EFFECTS OF STING AGONISTS AND STAT3 INHIBITORS
… of cytosolic DNA and the activation of STING pathways in tumor cells. The DNA sensors that recognize cytosolic DNA in tumor cells are not known. Here we show that double-stranded DNA and RNA:DNA hybrids bind cGAS and activate the cGAS-STING pathway in tumor cells. STING deficiency in …
-
Development and Characterization of Dendritic Cell-Targeted Polymers for Cancer Immunotherapy
Cancer vaccines and immunomodulators such as STING agonists hold great promise as cancer therapeutics but face many delivery challenges. In this work, we used polymers to deliver peptide antigens and STING agonists to dendritic cells to enhance therapeutic outcomes while minimizing off-target …
-
Understanding STING-mediated cytokine release and antitumor immunity in malignant pleural mesothelioma cell lines
… which to deploy stimulator of interferon genes (STING) agonists (Knelson et al., manuscript in revision). When activated, the STING pathway initiates an innate immune response through the release of pro-inflammatory cytokines and chemokines (Su et al., 2019). Stimulation of this pathway can …
-
Local or Systemic Antibody-Targeted Sting Activation Drives Pro- Inflammatory Stromal Metabolic Changes and Downregulates c-MYC Oncoprotein
… has emerged as a cornerstone, achieving long-lasting tumor regression in several types of cancer. However, its effectiveness is often limited, particularly in certain tumor types. Immunologically "cold" tumors, such as pancreatic ductal adenocarcinoma (PDAC), remain clinically unresponsive to …
-
Type I Interferon Responses in Monocytes Regulate GITRL Expression and Anti-tumor Immunity
… affects anti-tumor immunity in the context of STING agonist therapy of cancer. The cyclic GMP-AMP synthase stimulator of interferon genes (cGAS-STING) pathway allows cells to produce IFN-Is upon detection of cytosolic DNA and intratumoral injection of STING agonists drives durable and systemic …
-
Cancer-Cell-Derived cGAMP Promotes STING-Dependent Tumor Control but Limits CD8$^t{+}$ T Cell Activity
… Recognition of this DNA via the cGAS-cGAMP-STING pathway triggers the production of type I interferons and promotes anti-tumor immunity. It has been previously demonstrated that cancer-cell-derived cGAMP can be transferred to other cells in the tumor microenvironment, resulting in activation …
-
Multidomain Peptide Biomaterials for Enhanced Delivery of Anti-Cancer Immunotherapies
… first project, a Stimulator of Interferon Genes (STING) agonist was delivered from a cationic MDP hydrogel via intratumoral injection, showing direct cancer cell cytotoxicity and 6-fold enhanced tumor treatment efficacy compared to STING agonist alone. More advanced formulations were also …
-
Regulation of the cGAS-STING Pathway: Non-Agonist Activation and Cellular Trafficking
The cGAS-STING pathway in the innate immune system plays an important role in infection and cancer. Exogenous or endogenous DNA and cyclic dinucleotides acutely activate cGAS-STING, leading to type I interferon (IFN) signaling. STING-mediated IFN signaling is dynamically regulated by STING …
-
Design and synthesis of clickable nucleic acid analogues for cancer therapy and diagnosis
… In the first part the development of a series of STING agonists is described. STING is a key protein in the regulation of the innate immune system. The activation of the STING pathway begins when DNA is released in the cytosol. This DNA is seen by cells as a clear danger sign upon which the DNA …
-
MECHANISMS OF MICROBIOTA‑DRIVEN IMMUNE REGULATION IN THE TUMOR MICROENVIRONMENT
… stimulator of interferon genes (STING) agonists in driving type I interferon (IFN) responses in intratumoral monocytes. Such signals program immunostimulatory macrophages and enhance crosstalk between natural killer and dendritic cells. In addition, microbiota-targeted …
-
Investigating the effects of cGAS-STING-dependent innate immune responses in BRCA2-deficient cells
… BRCA2 depletion was shown to activate the cGAS-STING-dependent innate immune responses which have the potential to promote antitumour immunity. In this project, we set out to investigate the effects of stimulating the cGAS-STING-dependent innate immune responses using the STING agonist DMXAA in …
-
Engineering Bacterial Secretion of 2’3’ cGAMP for Therapeutics
… of the stimulator of interferon genes (STING) pathway within the last two decades has spurred the development of STING agonists as potential immunotherapeutics for the treatment of cancer and as vaccine adjuvants for infectious diseases. In this dissertation we have engineered …
-
RECOMBINANT BCG OVEREXPRESSING C-DI-AMP DEMONSTRATES ENHANCED IMMUNOGENICITY AND ENHANCED ANTI-TUMOR CYTOTOXICITY IN MNU-INDUCED BLADDER CANCER
STING-dependent Type I IFN responses have taken on heightened interest with the realization that STING agonists could be an important adjunct therapy to the cell-cycle check point inhibitors being used against several cancers. Intravesical instillation of BCG remains at the heart of bladder cancer …
-
Intratumoral Sting Activation Sensitizes Poorly Immunogenic Cancers to Checkpoint Blockade Immunotherapy
… component stimulator of interferon genes (STING) could reprogram tumor associated macrophages (TAMs) and myeloid derived suppressor cells (MDSCs) to support rather than suppress T cell activity, converting CRPC and PDAC to settings in which checkpoint blockade can be effective. To this end, …
-
Evaluation of cyclic dinucleotides and their prodrugs in biochemical and cellular assays
… regulating the cancer immunity cycle. The cGAS-STING pathway is one of the key pathways resulting in type I interferon mediated immune response. The cGAS-STING pathway is activated by double-stranded DNA (dsDNA) leaking into the cytosol. When cGAS (cytosolic-Guanosine-Adenosine-Synthase) binds …
-
Microbubble-Assisted Ultrasound Guided Immunotherapy of Cancer: A Novel Microbubble Platform for Cancer Immunotherapy
… synthase-stimulator of interferon genes (cGAS-STING) pathway has recently emerged as a potential therapeutic target to boost antitumor immune responses. cGAS-STING is crucial for priming adaptive antitumor immunity through antigen-presenting cells (APCs). Natural agonists such as cyclic …
-
Toward the Rational Design of Better Antivirals: The Development of cGAMP as an HIV-1 Anti-Retroviral and the Genetic Surveillance of WNV Evolution
… mechanisms to evade immune detection by the cGAS-STING cytosolic DNA sensing pathway. A small cyclic di-nucleotide, cGAMP, activates the same pathway by directly binding STING. Treatment with cGAMP, delivered by ultra-pH sensitive nanoparticles or by liposomes, in human peripheral blood …
-
The Role of the cGAS-STING Pathway in Cancer and Autoimmunity
… activates the stimulator of interferon genes (STING) protein to induce type I interferons, inflammatory cytokines, and autophagy. The cGAS-STING pathway played a critical role in cancer immune surveillance by detecting tumor-derived DNA. Furthermore, stimulating the pathway using STING agonists …
-
Understanding the role of TMEM33 in modulating host STING and the tumour immune microenvironment
… E3 ubiquitin ligases and their cofactors. STING (STimulator of INterferon Genes) is an ER-localised immune adaptor protein which in host antigen presenting cells (APCs) drives type I interferon-dependent anti-tumour immunity. Understanding its endogenous regulation is paramount for …
Page 1 of 2